ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus
- Registration Number
- NCT04835441
- Lead Sponsor
- Alpine Immune Sciences, Inc.
- Brief Summary
This is Phase 2, multinational, randomized, blinded study to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics and pharmacodynamics of ALPN-101 (acazicolcept) in adults with moderate to severe active systemic lupus erythematosus (SLE)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 76
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description ALPN-101 (acazicolcept) ALPN-101 - Placebo Placebo -
- Primary Outcome Measures
Name Time Method Adverse Events From study Day 1 until End of Study (28 weeks) Type, incidence, and severity of adverse events as assessed by CTCAE
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (46)
Investigational Site (173)
๐บ๐ธIdaho Falls, Idaho, United States
Investigational Site (118)
๐บ๐ธColleyville, Texas, United States
Investigational Site (191)
๐ต๐ทCaguas, Puerto Rico
Investigational Site (187)
๐ต๐ทSan Juan, Puerto Rico
Investigational Sites (134)
๐บ๐ธMiami, Florida, United States
Investigational Site (155)
๐บ๐ธLos Angeles, California, United States
Investigational Site (107)
๐บ๐ธAnniston, Alabama, United States
Investigational Site (120)
๐บ๐ธHialeah, Florida, United States
Investigational Site (106)
๐บ๐ธDeBary, Florida, United States
Investigational Site (152)
๐บ๐ธOrmond Beach, Florida, United States
Investigational Site (133)
๐บ๐ธPlantation, Florida, United States
Investigational Site (190)
๐บ๐ธTamarac, Florida, United States
Investigational Site (156)
๐บ๐ธSkokie, Illinois, United States
Investigational Site (138)
๐บ๐ธGrand Blanc, Michigan, United States
Investigational Site (179)
๐บ๐ธCharlotte, North Carolina, United States
Investigational Site (112)
๐บ๐ธCrossville, Tennessee, United States
Investigational Site (161)
๐ซ๐ทParis, France
Investigational Site (186)
๐บ๐ธMemphis, Tennessee, United States
Investigational Site (171)
๐บ๐ธBaytown, Texas, United States
Investigational Site (143)
๐บ๐ธBellaire, Texas, United States
Investigational Site (121)
๐บ๐ธHouston, Texas, United States
Investigational Site (166)
๐บ๐ธFort Worth, Texas, United States
Investigational Site (149)
๐ซ๐ทMarseille, France
Investigational Site (183)
๐ญ๐บSzรฉkesfehรฉrvรกr, Hungary
Investigational Site (128)
๐ซ๐ทParis, France
Investigational Site (180)
๐ญ๐บGyula, Hungary
Investigational Site (110)
๐ต๐ฑKrakรณw, Poland
Investigational Site (108)
๐ต๐ฑPoznaล, Poland
Investigational Site (165)
๐ต๐ฑWrocลaw, Poland
Investigational Site (137)
๐ช๐ธCoruna, Spain
Investigational Site (139)
๐ช๐ธSevilla, Spain
Investigational Site (184)
๐จ๐ณTaichung, Taiwan
Investigational Site (175)
๐บ๐ธBrooklyn, New York, United States
Investigational Site (169)
๐บ๐ธSanta Barbara, California, United States
Investigational Site (115)
๐บ๐ธManhasset, New York, United States
Investigational Site (104)
๐บ๐ธMesquite, Texas, United States
Investigational Site (182)
๐จ๐ณTaipei, Taiwan
Investigational Site (119)
๐ต๐ฑPoznaล, Poland
Investigational Site (181)
๐ญ๐บBudapest, Hungary
Investigational Site (160)
๐ต๐ฑElblฤ g, Poland
Investigational Site (189)
๐บ๐ธPhoenix, Arizona, United States
Investigational Site (109)
๐บ๐ธSan Diego, California, United States
Investigational Site (163)
๐บ๐ธTampa, Florida, United States
Investigational Site (164)
๐บ๐ธLas Vegas, Nevada, United States
Investigational Site (162)
๐บ๐ธSan Antonio, Texas, United States
Investigational Site (127)
๐บ๐ธSan Antonio, Texas, United States